Latest Annexin Pharmaceuticals News & Updates

See the latest news and media coverage for Annexin Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Annexin Pharmaceuticals

Clinical-stage biotechnology company developing Annexin A5 therapeutics

annexinpharma.com

Headquarters: Stockholm, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 5–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Annexin Pharmaceuticals

In short: Annexin Pharmaceuticals reported positive Phase 2a data for its drug vanexin in eye diseases and secured funding via several rights issues.

Company announcements

July 3 Annexin Pharmaceuticals

Annexin's rights issue was 98 percent subscribed

The subscription period ended on 2 July 2026, and the company will receive 19.9 MSEK before costs.

June 23 Annexin Pharmaceuticals

Annexin Pharmaceuticals reports positive data from NEXUS study in DR and RVO

Treatment with ANXV showed improved retinal perfusion and was well tolerated, supporting further development.

June 3 Annexin Pharmaceuticals

Annexin resolves a SEK 20 million rights issue, 60% secured

The issue includes an overallotment option of up to SEK 5 million to fund phase 2a study NEXUS.

April 22 Annexin Pharmaceuticals

Annexin accelerates patient recruitment in NEXUS study

Five patients treated for RVO and DR with no safety issues. Promising initial results observed. Recruitment continues.

Media coverage

August 21 Finanzen.ch

Annexin Pharmaceuticals Registered reported figures for the most recent quarter

Annexin Pharmaceuticals Registered presented the balance sheet figures for the year quarter ending on June 30, 2026, on August 21, 2026. Regarding EPS, a...

July 3 Affärsvärlden

Annexin: Almost fully subscribed despite meager discount

Annexin Pharmaceuticals' rights issue of shares was subscribed to 97.9% and the company thus receives SEK 19.9 million before expenses. Emissionsguiden raises a flag.

June 23 FinanzNachrichten.de

Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been...

June 17 Affärsvärlden

Coverage of Annexin's rights issue begins

Annexin Pharmaceuticals' rights issue can provide the company with 20.3 million SEK before costs.

Never miss news about Annexin Pharmaceuticals

Track Annexin Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Annexin Pharmaceuticals competitors & trending companies

Browse news for competitors to Annexin Pharmaceuticals and other trending companies.